Drug Database
ME

meningococcal meningitis conjugate vaccine (Manhaixin / Menhycia)

✓ Approved

CanSino Biologics · Cell-based Therapies · Cell-based Therapies

What is meningococcal meningitis conjugate vaccine?

meningococcal meningitis conjugate vaccine is a cell-based therapies developed by CanSino Biologics. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesManhaixin, Menhycia
CompanyCanSino Biologics
Drug ClassCell-based Therapies, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved

Therapeutic Indications

meningococcal meningitis conjugate vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedmSphere2026-11-11

Genetic detoxification of an unencapsulated Neisseria meningitidis strain enhances potency of outer membrane vesicle vaccines and cross-reactivity of vaccine-specific antibodies.

Matthias Kathryn A KA, Kumova Ogan K OK, Reveille Alexandra A, Bizzell Erica E et al.

Meningococcal serogroup B (MenB) detergent-detoxified outer membrane vesicle (dOMV) vaccines demonstrate high effectiveness against the homologous production strain but confer limited cross-protection to heterologous strains. We previously reported that dOMVs isolated from a MenB strain deleted for the proteins PorA, PorB, and RmpM (ΔABR) elicited bactericidal antibodies with a greater breadth of coverage, but of lower overall titer, compared to wild-type (WT) dOMV-induced antibodies. Low ΔABR dOMV potency was associated with pronounced vesicular deterioration and lower levels of lipooligosaccharide (LOS) and capsular polysaccharide (Cps) relative to WT dOMVs, phenotypes resulting from detergent detoxification procedures required to limit LOS-induced toxicity. In this study, we engineered genetically detoxified ΔABR strains that were deleted singly for the lauroyl acyltransferase LpxL1 (ΔABRL) or in tandem for the Cps polysialyltransferase SiaD (ΔABRSL). Genetically detoxified, detergent-extracted OMVs (eOMVs) from ΔABRL and ΔABRSL retained vesicular structure and elicited functional antibodies with increased cross-reactivity compared to ΔABR and ΔABRL dOMVs when administered to rabbits. Antibody seropositivity and cross-reactivity were similarly increased in mice vaccinated with ΔABRL eOMVs vs ΔABRL dOMVs. ΔABRSL eOMV potency was higher than that of ΔABRL eOMVs, suggesting a role for Cps in suppressing antibody responses. Immunization with eOMVs was associated with trends toward improved murine T helper cell responses and elicitation of higher proportions of conformational antibodies that may have contributed to improved bactericidal activity. ΔABRSL eOMVs additionally showed decreased toxicity compared to WT and ΔABR dOMVs when tested in vitro, supporting further study as a vaccine candidate. The ability to target multiple serogroup B Neisseria meningitidis strains with a single vesicle vaccine is complicated by the diversity of antigens that span the bacterial surface. We previously reported that vesicles isolated from meningococcal strains deleted for the major antigenically diverse surface proteins elicited functional antibodies that could kill a large number of N. meningitidis strains though at relatively low titers. Low potency of the mutant vaccines was associated with a breakdown of the vesicular membrane upon detergent treatment, a process necessary to diminish endogenous endotoxin levels and ensure vaccine safety. In this study, we demonstrate that we can retain high cross-reactivity of anti-vesicle antibodies without decreasing the potency of the host immune response through genetic detoxification of the meningococcal vaccine strain. By preventing the formation of the complete endotoxin structure, we are able to isolate vesicles that are safe and immunogenic without the requirement for detergent detoxification.

PubMedKlinicka mikrobiologie a infekcni lekarstvi2026-11-11

[Diagnosis and treatment of cryptococcal meningitis].

Stebel Roman R, Foltýnová Gabriela G

Cryptococcal meningitis represents a serious opportunistic fungal neuroinfection associated with high mortality, particularly in patients with impaired cellular immunity. Although the disease is traditionally linked to advanced HIV infection, in recent years, we have observed an increasing number of cases in non-HIV patients as well. The article summarizes current knowledge on the etiopathogenesis, clinical presentation, diagnosis, and treatment of this condition. Emphasis is placed on the importance of early diagnosis through detection of the cryptococcal antigen and molecular genetic methods, which significantly accelerate establishment of the diagnosis. Treatment requires a comprehensive multidisciplinary approach encompassing induction, consolidation, and maintenance antifungal therapy, with the combination of liposomal amphotericin B and flucytosine followed by triazole antifungals remaining the standard of care. The article also includes a case report of a young HIV-negative patient with meningitis caused by Cryptococcus neoformans. While searching for secondary immunodeficiency, the patient was diagnosed with sarcoidosis - a condition itself representing a strong predisposing factor associated with impaired cellular immunity. Thus, the case report underscores the necessity of considering cryptococcosis even in seemingly immunocompetent individuals and of always searching for an underlying immunodeficiency. Keywords: cryptococcal meningitis, Cryptococcus neoformans, sarcoidosis, opportunistic mycosis.

PubMedKlinicka mikrobiologie a infekcni lekarstvi2026-11-11

[Central nervous system involvement in HIV-infected individuals].

Rozsypal Hanuš H

Central nervous system (CNS) involvement can occur at any time during human immunodeficiency virus (HIV) infection. Diseases can be primary, caused directly by HIV, or secondary, caused by other agents or induced by other mechanisms, especially tumors and vascular causes. Worsening cellular immunodeficiency creates conditions for opportunistic infections to occur. These include three typical diseases: toxoplasmic encephalitis, cryptococcal meningitis, and progressive multifocal leukoencephalopathy. Antiretroviral therapy has dramatically changed the occurrence of nervous system complications. Opportunistic infections have decreased, and primary cerebral lymphoma is now rare. However, even with effective regimens, at least minimal signs of HIV-associated neurocognitive disorder can be found in many patients. The nervous system can be affected by syphilis, which may present differently in HIV-positive individuals due to the higher risk of treponemal invasion of the CNS. Keywords: human immunodeficiency virus (HIV) infection, HIV-associated neurocognitive disorder (HAND), opportunistic infection, brain toxoplasmosis, progressive multifocal leukoencephalopathy (PML), cryptococcal meningitis, neurosyphilis.

PubMedNPJ vaccines2026-11-11

A structure-guided trivalent subunit vaccine confers maternal protection to neonatal piglets against PEDV and PDCoV.

Liu Jia J, Chen Longping L, Li Dan D, Wang Zhuo Z et al.

Antigenic divergence among porcine epidemic diarrhea virus (PEDV) genotypes and porcine deltacoronavirus (PDCoV) limits the cross-protection provided by current commercial vaccines. Here, employing a structure-guided antigen design strategy, we developed a trivalent subunit vaccine concurrently targeting PEDV G2a, PEDV G2b, and PDCoV. The vaccine antigen set comprises optimized spike ectodomain antigens, featuring stabilizing mutations, a heptad repeat 2 (HR2) deletion, a fused neutralizing epitope, and a flagellin adjuvant fused to the N-terminus. Formulated with MF59+CpG adjuvants, this trivalent vaccine elicited robust PEDV- and PDCoV-specific neutralizing antibody responses and Th1/Th2-associated cellular immune responses characterized by IFN-γ, IL-2, and IL-4 production in mice. Immunization of pregnant sows with 300 μg dose induced high-titer IgG, IgA, and colostral secretory IgA (SIgA) against all three target viruses. Although neutralizing antibody titers were comparable between the 100 μg and 300 μg dose groups, the 300 μg group showed higher and more persistent levels of colostral binding IgG and SIgA. Following maternal immunization, piglets that acquired maternal antibodies through colostrum exhibited reduced clinical diarrhea, lower fecal viral RNA shedding, and less severe intestinal lesions after challenge with PEDV G2a, PEDV G2b, or PDCoV. These findings support this structure-guided trivalent subunit vaccine as a promising candidate for maternal immunization against co-circulating porcine enteric coronaviruses.

PubMedKlinicka mikrobiologie a infekcni lekarstvi2026-11-11

[Fosfomycin for treating neurological infections].

Fric Milan M, Ryšková Lenka L

Intravenous fosfomycin, an antibiotic known for decades, is increasingly being clinically used as a reserve component of combination antimicrobial therapy for a wide range of indications. Its pharmacokinetic properties and unique mechanism of action offer numerous advantages in treating the most severe central nervous system infections. Its importance is growing alongside the rising prevalence of infections - particularly nosocomial ones - caused by resistant bacteria. Intravenous fosfomycin offers a favorable safety profile and high efficacy within combination treatment regimens. Keywords: intravenous fosfomycin, CNS infections, meningitis, ventriculitis, antibiotic resistance, external ventricular drainage.

PubMedHealth communication2026-11-11

Spiritual Health Locus of Control and COVID-19 Booster Intentions Among Hispanic Americans: A Culturally Grounded Extension of the Extended Parallel Process Model.

Kim Joon J, Jun Jungmi J, Zambrano Rodriguez Viviana Carolina VC

Declining uptake of COVID-19 boosters poses significant public health concerns. Hispanic Americans, who have experienced disproportionate pandemic impacts, report lower uptake of updated boosters than non-Hispanic White adults, partly attributable to vaccine hesitancy. Although religiosity plays a central role in Hispanic communities, little is known about how spiritually grounded beliefs shape cognitive and emotional responses to vaccination. This study integrates the extended parallel process model (EPPM) with spiritual health locus of control (SHLOC) to examine how exposure to faith-based and governmental vaccine information influences booster intention through spiritually grounded efficacy appraisals. Using an online survey of Hispanic American adults (N = 349), we tested a structural equation model linking SHLOC, perceived threat, efficacy beliefs, fear, and vaccination intentions. Results indicated that active SHLOC, reflecting beliefs in divine partnership in health, increased response efficacy and indirectly promoted booster intention and vaccine advocacy, whereas passive SHLOC, reflecting divine determinism, reduced self-efficacy and indirectly discouraged booster intention. Perceived threat was positively associated with fear, and efficacy beliefs emerged as the strongest predictors of booster intention. Mediation analyses supported serial pathways from message exposure to SHLOC to efficacy to intention, identifying spiritually grounded control beliefs as a culturally embedded mechanism in vaccine decision making. Findings suggest that faith-based engagement can function as either a protective or risk communication channel, depending on whether messages reinforce divine partnership or determinism. The study advances EPPM by identifying SHLOC as a culturally grounded antecedent to efficacy appraisal and offers implications for culturally responsive vaccine communication in Hispanic communities.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal meningitis conjugate vaccine